@FierceMedDev: ICYMI yesterday: Welch Allyn partners with startup Gentag to create wearable devices. Article | Follow @FierceMedDev
@VarunSaxena2: UPDATED: Dx company Alere sells its health services unit for $600M amid continued restructuring. More | Follow @VarunSaxena2
@EmilyWFierce: Au revoir, Viehbacher. Reuters article | Follow @EmilyWFierce
> Portable oxygen concentrator company Inogen ($INGN) announced a proposed secondary public offering of 2.1 million shares, which would raise about $47 million. Release
> Zoll Medical, a manufacturer of medical devices and related software solutions, has agreed to acquire for an undisclosed sum all of the assets of Impact Instrumentation, a manufacturer of respiratory care products. Release
> Enlitic, a startup focused on using a kind of artificial intelligence to help doctors in with diagnosis and prognosis of diseases, announced a $2 million seed round. Story
> An average price drop of 5% hit top-10 physician preferred medical devices this August compared to the same period last year. Report
Biotech News
@FierceBiotech: Armed with $48M bankroll, Aileron sets sights on p53 tumor target. Article | Follow @FierceBiotech
@JohnCFierce: $JNJ in China, deals getting struck on drug rights. Lots coming in Asia for biopharma. It's the new, new thing | Follow @JohnCFierce
@DamianFierce: "Categorical" second only to "fundamental" in corporate nonsensespeak--$AEGR. More from TheStreet | Follow @DamianFierce
@EmilyMFierce: Brain cells reprogrammed from skin cells offer treatment hope for Huntington's. FierceBiotechResearch story | Follow @EmilyMFierce
> Cara's pain drug clears an abuse hurdle as it trots toward Phase III. News
> Xencor moves on without Amgen, ditching its hopes in arthritis. More
> Scripps cancer spinout Xcovery grabs $20M from a pharma partner in China. Article
Pharma News
@FiercePharma: Top-read in FiercePharmaManufacturing Tues: Production issues for $GSK, Sanofi delay flu vaccines in the U.S. Article | Follow @FiercePharma
@EricPFierce: Ranbaxy's Ohm Laboratories plant comes to the rescue in last quarter, turning bottom line from red to black. FiercePharmaManufacturing story | Follow @EricPFierce
@CarlyHFierce: ICYMI yesterday: Pharma's top 10 M&A deals of H1 2014. Feature | Follow @CarlyHFierce
> Like Novartis before it, AstraZeneca benefits big time from Ranbaxy issues. Report
> Sanofi canned its outspoken CEO. Will the board go French with a replacement? More
> Gilead misses the mark in Q3 due to Obamacare fee and dip in Sovaldi revenue. Story
Drug Delivery News
> Eye care company pSivida receives royalty payment, will spend it on pipeline. More
> BDSI aiming to develop injectable buprenorphine. Item
> Harvard team uses stem cells to deliver toxic doses to cancer cells. Report
> Microscale fibers may have many drug-delivery uses. Story
> Pfizer to withdraw from partnership to develop tamper-proof oxycodone formulation. Article
Diagnostics News
> InSilixa ropes in $13M from PointGuard Ventures and Morningside for molecular Dx tests. Story
> Johns Hopkins scientists develop real-time diagnostic system for drug-resistant bacteria. More
> FDA grants bioMérieux emergency authorization for one-hour Ebola Dx. Item
> 'See-through' sensors for the brain are transparent to imaging diagnostics. Story
> French scientists roll out rapid diagnostic test for Ebola. Article
Pharma Marketing News
> Love to hate Mr. Mucus? The Mucinex snot monster is back with a McCann makeover. Report
> For Novartis' respiratory ambitions, it's a tale of 'two worlds.' Story
> Sanofi board ousts CEO, aiming for a more 'cooperative' chief. Item
> Who's the diabetes price-cutting culprit: Lilly, Sanofi or Novo? More
> Orphan drug pricing for non-orphan meds? Express Scripts is looking at you, Gilead. Article